Ziconotide: a clinical update and pharmacologic review.

Abstract

INTRODUCTION:

Ziconotide is an N-type calcium channel antagonist to treat chronic pain that is delivered intrathecally. It is the only intrathecal, FDA-approved, non-opioid analgesic and is recommended as first-line therapy. Despite these advantages, a small therapeutic window limits ziconotide's clinical utility, with adverse event (AE) challenges that include, but are not limited to, dizziness, nausea, and somulence.

AREAS COVERED:

Pharmacokinetics, pharmacodynamics, efficacy, safety, trialing, and chronic infusion after searching EMBASE, PubMed, and Cochrane Database of Systemic Reviews were used to search published literature from 1966 to January 1, 2013 to identify studies related to the intrathecal delivery of ziconotide.

EXPERT OPINION:

Ziconotide is a safe and effective strategy to treat chronic pain, although limitations remain, including a small therapeutic window. Low starting doses and slow incremental increases and long titration intervals may improve tolerability. AEs may be mitigated by also employing combination therapy, although further study is needed. Concomitant use of ziconotide and morphine is an option when considering use of FDA-labeled intrathecal drugs in those resistant to monotherapy.

• Authors: Jason E Pope, Timothy R Deer
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 14 Issue 7 Pg. 957-66 (May 2013) ISSN: 1744-7666 [Electronic] England
• PMID: 23537340 (Publication Type: Journal Article, Review)

Chemical References

• Analgesics, Non-Narcotic
• Calcium Channel Blockers
• omega-Conotoxins
• ziconotide

Topics

• Analgesics, Non-Narcotic (administration & dosage, adverse effects, therapeutic use)
• Calcium Channel Blockers (administration & dosage, adverse effects, therapeutic use)
• Chronic Pain (drug therapy)
• Clinical Trials as Topic
• Humans
• Injections, Spinal
• omega-Conotoxins (administration & dosage, adverse effects, therapeutic use)